Veri Medtech Holdings(VRHI)
$4.410.00 (0.00%)
VRHI
Veri Medtech Holdings financials statements
$4.41
At close:0.00 (0.00%)
Veri Medtech Holdings (VRHI) Ratios
5 Followers
Veri Medtech Holdings Ratios
VRHI's free cash flow for Q3 2026 was $33.06K. For the 2026 fiscal year, VRHI's free cash flow was decreased by $-4.00 and operating cash flow was $33.06K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.05 | ― | 1118.25 | 0.00 | 0.68 |
| Quick Ratio | 0.05 | ― | 1118.25 | 0.00 | 0.68 |
| Cash Ratio | 0.02 | ― | 1118.25 | 0.00 | 0.68 |
| Solvency Ratio | -0.87 | ― | -14.13 | -0.63 | -0.11 |
| Operating Cash Flow Ratio | 0.13 | ― | -4848.75 | 0.00 | -0.23 |
| Short-Term Operating Cash Flow Coverage | 0.61 | ― | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -2.42M | ― | $ 22.59K | $ -28.96K | $ -86.80K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.83 | ― | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -0.22 | ― | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | -0.28 | ― | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.08 | ― | 1.03 | 1.28 | 4.49 |
| Debt Service Coverage Ratio | -3.65 | ― | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -33.28 | ― | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.02 | ― | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.07 | ― | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.22 | ― | 0.45 | 0.80 | 5.97 |
| Profitability Margins | |||||
| Gross Profit Margin | 75.28% | ― | 85.49% | 83.05% | 76.53% |
| EBIT Margin | -20.89% | ― | -79.26% | -156.70% | -454.71% |
| EBITDA Margin | -19.84% | ― | -76.75% | -154.75% | -62.99% |
| Operating Profit Margin | -20.89% | ― | -79.26% | -156.70% | -454.71% |
| Pretax Profit Margin | -21.53% | ― | -79.26% | -156.70% | -65.96% |
| Net Profit Margin | -21.53% | ― | -79.26% | -156.70% | -65.96% |
| Continuous Operations Profit Margin | -21.53% | ― | -79.26% | -156.70% | -454.71% |
| Net Income Per EBT | 100.00% | ― | 100.00% | 99.99% | 100.00% |
| EBT Per EBIT | 103.05% | ― | 100.00% | 100.00% | 14.51% |
| Return on Assets (ROA) | -1263.34% | ― | -37.20% | -13.81% | -9.29% |
| Return on Equity (ROE) | 98.92% | ― | -38.17% | -17.64% | -41.75% |
| Return on Capital Employed (ROCE) | 95.99% | ― | -37.20% | -13.81% | -287.82% |
| Return on Invested Capital (ROIC) | 123.26% | ― | -37.20% | -13.81% | -287.82% |
| Return on Tangible Assets | -1263.34% | ― | -37.20% | -13.81% | -9.29% |
| Earnings Yield | -9.34% | ― | -0.43% | -0.15% | -0.09% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1643.67 | ― | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.87 | ― | 472.29 | 0.00 | 0.04 |
| Inventory Turnover | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 181.58 | ― | 10.38 | 0.43 | 0.82 |
| Asset Turnover | 58.68 | ― | 0.47 | 0.09 | 0.14 |
| Working Capital Turnover Ratio | -4.40 | ― | 2.61 | -0.94 | 1.75 |
| Cash Conversion Cycle | -195.35 | ― | -0.77 | 0.00 | -8584.54 |
| Days of Sales Outstanding | 0.22 | ― | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 195.57 | ― | 0.77 | 0.00 | 8584.54 |
| Operating Cycle | 0.22 | ― | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.04 | ― | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | 0.04 | ― | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 102.77 | ― | 0.00 | 0.00 | -62.15 |
| Capital Expenditure Coverage Ratio | 102.77 | ― | 0.00 | 0.00 | -62.15 |
| Operating Cash Flow Coverage Ratio | 0.61 | ― | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.03 | ― | -1.49 | -1.65 | -1.26 |
| Free Cash Flow Yield | 1.26% | ― | -0.80% | -0.16% | -0.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.43 | ― | -236.36 | -685.71 | -168.64 |
| Price-to-Sales (P/S) Ratio | 2.30 | ― | 185.04 | 1060.36 | 761.60 |
| Price-to-Book (P/B) Ratio | -10.59 | ― | 89.12 | 119.34 | 482.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 79.06 | ― | -124.22 | -642.96 | -595.72 |
| Price-to-Operating Cash Flow Ratio | 78.29 | ― | -124.22 | -642.96 | -605.31 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | ― | -4.14 | 8.15 | -2.02 |
| Enterprise Value Multiple | -11.84 | ― | -240.64 | -684.39 | -1203.18 |
| Enterprise Value | 25.48M | ― | 14.43M | 26.66M | 37.36M |
| EV to EBITDA | -11.84 | ― | -240.64 | -684.39 | -1203.18 |
| EV to Sales | 2.35 | ― | 184.69 | 1059.13 | 757.84 |
| EV to Free Cash Flow | 80.57 | ― | -123.99 | -642.22 | -592.78 |
| EV to Operating Cash Flow | 79.79 | ― | -123.99 | -642.22 | -602.32 |
| Tangible Book Value Per Share | -0.30 | ― | 0.00 | 0.00 | 0.00 |
| Shareholders’ Equity Per Share | -0.30 | ― | 0.00 | 0.00 | 0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.36 | ― | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.29 | ― | -0.00 | -0.00 | -0.00 |
| Tax Burden | 1.00 | ― | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.03 | ― | 1.00 | 1.00 | 0.15 |
| Research & Development to Revenue | 0.00 | ― | 0.00 | 0.00 | 0.04 |
| SG&A to Revenue | 0.96 | ― | 1.65 | 2.40 | 0.17 |
| Stock-Based Compensation to Revenue | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.14 | ― | 1.88 | 1.05 | 1.91 |
Currency in USD

